trial · primary record
TAK-788
Carcinoma, Non-Small-Cell Lung
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | COMPLETED |
| Sponsor | Unknown |
| Enrolment | 324 |
| Primary completion | 2026-09-29 |
| Primary endpoint | Part 1, Dose Escalation Component: Recommended Phase 2 Dose (RP2D) of Orally Administered TAK-788 |
| Registry ID | NCT02716116 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:40:56.586Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT02716116
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.